Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Background: For patients with chronic, non-cancer pain, traditional pain-relieving medications include opioids, which have shown benefits but are associated with increased risks of addiction and adverse effects. Medical cannabis has emerged as a treatment alternative for managing these patients and there has been a rise in the number of randomized clinical trials in recent years; therefore, a systematic review of the evidence was warranted. Objective: To analyze the evidence surrounding the benefits and harms of medical cannabinoids in the treatment of chronic, non-cancer-related pain. Design: Systematic review with meta-analysis. Data sources: Medline, Embase, CINAHL, SCOPUS, Google Scholar, and Cochrane Databases. Eligibility criteria: English language randomized clinical trials of cannabinoids for the treatment of chronic, non-cancer-related pain. Data extraction and synthesis: Study quality was assessed using the Cochrane risk of bias tool. All stages were conducted independently by a team of 6 reviewers. Data were pooled through meta-analysis with different durations of treatment (2 weeks, 2 months, 6 months) and stratified by route of administration (smoked, oromucosal, oral), conditions, and type of cannabinoids. Main outcomes and measures: Patient-reported pain and adverse events (AEs). Results: Thirty-six trials (4006 participants) were included, examining smoked cannabis (4 trials), oromucosal cannabis sprays (14 trials), and oral cannabinoids (18 trials). Compared with placebo, cannabinoids showed a significant reduction in pain which was greatest with treatment duration of 2 to 8 weeks (weighted mean difference on a 0-10 pain visual analogue scale −0.68, 95% confidence interval [CI], −0.96 to −0.40, I 2 = 8%, P < .00001; n = 16 trials). When stratified by route of administration, pain condition, and type of cannabinoids, oral cannabinoids had a larger reduction in pain compared with placebo relative to oromucosal and smoked formulations but the difference was not significant ( P[interaction] > .05 in all the 3 durations of treatment); cannabinoids had a smaller reduction in pain due to multiple sclerosis compared with placebo relative to other neuropathic pain ( P[interaction] = .05) within 2 weeks and the difference was not significant relative to pain due to rheumatic arthritis; nabilone had a greater reduction in pain compared with placebo relative to other types of cannabinoids longer than 2 weeks of treatment but the difference was not significant ( P[interaction] > .05). Serious AEs were rare, and similar across the cannabinoid (74 out of 2176, 3.4%) and placebo groups (53 out of 1640, 3.2%). There was an increased risk of non-serious AEs with cannabinoids compared with placebo. Conclusions: There was moderate evidence to support cannabinoids in treating chronic, non-cancer pain at 2 weeks. Similar results were observed at later time points, but the confidence in effect is low. There is little evidence that cannabinoids increase the risk of experiencing serious AEs, although non-serious AEs may be common in the short-term period following use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Human Cannabinoid Pharmacokinetics
Huestis, M. A. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790152 · Cited by 1,102
The endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090
Guyatt, G., Oxman, A. D., Sultan, S., Brozek, J., Glasziou, P., Alonso-Coello, P., Atkins, D., Kunz, R., Montori, V., Jaeschke, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.006 · Cited by 762
Guideline for opioid therapy and chronic noncancer pain
Busse, J. W., Craigie, S., Juurlink, D. N., Buckley, D. N., Wang, L., Couban, R. J., Agoritsas, T., Akl, E. A., Carrasco-Labra, A., Cooper, L., et al. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170363 · Cited by 707 · cited 1×
“We excluded (1) non-human or preclinical trials; (2) nonEnglish language trials; (3) trials reporting on acute or cancerrelated pain; (4) trials with less than 24-hours follow-up; (5) trials only reported as abstracts or posters, with no available full-text article; (6) pilot trials where patients overlapped with thos…”
MethodRandomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
Cannabinoid Receptors: Where They are and What They do
Mackie, K. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01671.x · Cited by 638
Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial
Abrams, D. I., Jay, C. A., Shade, S. B., Vizoso, H., Reda, H., Press, S., Kelly, M. E., Rowbotham, M. C., & Petersen, K. L. (2007) · Neurology · doi:10.1212/01.wnl.0000253187.66183.9c · Cited by 598
Wade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589
Cited by
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Peng, J., Fan, M., An, C., Ni, F., Huang, W., & Luo, J. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13710 · Cited by 282
Markovà, J., Essner, U., Akmaz, B., Marinelli, M., Trompke, C., Lentschat, A., & Vila, C. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1481066 · Cited by 151
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., & Dwan, K. (2022) · Cochrane Database Systematic Reviews · doi:10.1002/14651858.cd013444.pub2 · Cited by 75
Pain management strategies in rheumatoid arthritis: a narrative review
Sánchez-Flórez, J. C., Seija-Butnaru, D., Valero, E. G., Acosta, C. D. P. A., & Amaya, S. (2021) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2021.1973647 · Cited by 54
Recreational Cannabis Use Before and After Legalization in Women With Pelvic Pain
Geoffrion, R., Yang, E. C., Koenig, N. A., Brotto, L. A., Barr, A. M., Lee, T., Allaire, C., Bedaiwy, M. A., & Yong, P. J. (2021) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000004207 · Cited by 21
Metadata
- Authors
- Johal, H., Devji, T., Chang, Y., Simone, J., Vannabouathong, C., & Bhandari, M.
- Venue
- Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
- Publisher
- SAGE Publications
- Published
- 2020-01
- Volume
- 13
- Pages
- 117954412090646
- ISSN
- 1178-1149 (ISSN-L)
- 1179-5441
- OpenAlex
- W3007289662
- Cited by
- 105
- References
- 37
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.1177/1179544120906461
- The paper
- Johal, H., Devji, T., Chang, Y., Simone, J., Vannabouathong, C., & Bhandari, M. (2020). Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. https://doi.org/10.1177/1179544120906461
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.